Imunon Inc. has published a document detailing a Phase I/II study on the safety and efficacy of the investigational product IMNN-001, in combination with standard of care treatment, for patients newly diagnosed with advanced epithelial ovarian cancer. The document provides updated survival analysis from the OVATION-2 trial, highlighting the study's primary and secondary endpoints, including safety, progression-free survival, overall survival, and response rates. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.